Marinomed Biotech AG confirmed its financial outlook for the fiscal year 2022: The Company expects continued growth of Carragelose revenues and a slight increase in R&D expenses, and consequently an operating loss for 2022. Marinomed plans to reach operating profitability in the medium term.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.4 EUR | +0.61% | -3.24% | -43.84% |
16/04 | Transcript : Marinomed Biotech AG, 2023 Earnings Call, Apr 16, 2024 | |
16/04 | Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-43.84% | 27.27M | |
-3.02% | 89.69B | |
+2.50% | 41.34B | |
-12.01% | 33.72B | |
+62.74% | 26.11B | |
-19.79% | 14.63B | |
-8.58% | 12.84B | |
-12.34% | 11.66B | |
-43.92% | 11.52B | |
+4.27% | 8.92B |
- Stock Market
- Equities
- MARI Stock
- News Marinomed Biotech AG
- Marinomed Biotech AG Confirms Financial Outlook for the Fiscal Year 2022